Immunosuppressive networks in the tumour environment and their therapeutic relevance
暂无分享,去创建一个
[1] M. Raffeld,et al. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.
[2] G. Zhu,et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.
[3] P. Black,et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. , 2000, Cancer research.
[4] R. Offringa,et al. Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine , 2001, The Journal of experimental medicine.
[5] P. Matzinger. The Danger Model: A Renewed Sense of Self , 2002, Science.
[6] S. Jozefowski,et al. Exogenous but not endogenous prostanoids regulate cytokine secretion from murine bone marrow dendritic cells: EP2, DP, and IP but not EP1, EP3, and FP prostanoid receptors are involved. , 2003, International immunopharmacology.
[7] R. Offringa,et al. Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication1 , 2004, The Journal of Immunology.
[8] Fiona Powrie,et al. Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation , 2000, The Journal of experimental medicine.
[9] J. Moore,et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor , 1998, Nature Medicine.
[10] Lin Zhang,et al. Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A , 2004, Nature Medicine.
[11] Sayuri Yamazaki,et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance , 2001, Immunological reviews.
[12] N. Restifo,et al. Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.
[13] S. Rosenberg,et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.
[14] E. Shevach. Fatal attraction: tumors beckon regulatory T cells , 2004, Nature Medicine.
[15] I. M. Neiman,et al. [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.
[16] J. Blay,et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. , 1998, Blood.
[17] C. Uyttenhove,et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.
[18] B. Levin,et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.
[19] N. Mitsiades,et al. Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. , 1999, The Journal of clinical endocrinology and metabolism.
[20] A. Houghton,et al. Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells , 2004, The Journal of experimental medicine.
[21] R. Steinman,et al. Direct Expansion of Functional CD25+ CD4+ Regulatory T Cells by Antigen-processing Dendritic Cells , 2003, The Journal of experimental medicine.
[22] C. June,et al. Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation1 , 2002, The Journal of Immunology.
[23] T. Honjo,et al. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. , 2004, International immunology.
[24] D. Pardoll,et al. Does the immune system see tumors as foreign or self? , 2003, Annual review of immunology.
[25] Nicholas R. English,et al. Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.
[26] J. Masferrer,et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. , 2002, Cancer research.
[27] F. Foss. A Novel Fusion Toxin Therapy for Lymphoma , 2000 .
[28] C. Melief,et al. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. , 1992, Advances in cancer research.
[29] O. Finn,et al. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. , 2001, Cancer research.
[30] D. Klinman. Immunotherapeutic uses of CpG oligodeoxynucleotides , 2004, Nature Reviews Immunology.
[31] Thomas Davis,et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[32] P. Greenberg,et al. Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses , 2002, Nature Reviews Cancer.
[33] C. Atkinson,et al. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. , 1998, The Journal of urology.
[34] C. Dong,et al. B7S1, a novel B7 family member that negatively regulates T cell activation. , 2003, Immunity.
[35] Ruslan Medzhitov,et al. Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells , 2003, Science.
[36] J. Petersen,et al. Autoreactive CD4+ T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway. , 1999, Immunity.
[37] D. Munn,et al. IDO and tolerance to tumors. , 2004, Trends in molecular medicine.
[38] Scott N. Mueller,et al. Rapid Cytotoxic T Lymphocyte Activation Occurs in the Draining Lymph Nodes After Cutaneous Herpes Simplex Virus Infection as a Result of Early Antigen Presentation and Not the Presence of Virus , 2002, The Journal of experimental medicine.
[39] G. Zhu,et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. , 2003, Immunity.
[40] M. Noris,et al. Natural versus adaptive regulatory T cells. , 2005, Contributions to nephrology.
[41] Eli Gilboa,et al. The promise of cancer vaccines , 2004, Nature Reviews Cancer.
[42] T. Mak,et al. Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4 , 2000, The Journal of experimental medicine.
[43] J. Allison,et al. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[44] T. Mcclanahan,et al. Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.
[45] T. Eberlein,et al. Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.
[46] M. Nishimura,et al. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. , 2002, Immunity.
[47] Thomas A. Davis,et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[48] C. Atkinson,et al. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[49] K. Knutson,et al. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. , 2001, The Journal of clinical investigation.
[50] S. Hussain,et al. CD4+CD25+ Regulatory T Cells That Secrete TGFβ and IL-10 Are Preferentially Induced by a Vaccine Vector , 2004, Journal of immunotherapy.
[51] Andy Smith. Mapping the way , 2002, Trends in Neurosciences.
[52] A. Visintin,et al. Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism1 , 2002, The Journal of Immunology.
[53] M. Smyth,et al. Close encounters of different kinds: Dendritic cells and NK cells take centre stage , 2005, Nature Reviews Immunology.
[54] P. Kalinski,et al. Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. , 1998, Journal of immunology.
[55] G. Freeman,et al. Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1 , 2003, The Journal of Immunology.
[56] Lei Shen,et al. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity , 2004, Nature Biotechnology.
[57] Lieve Moons,et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. , 2005, Cancer research.
[58] A. Frey,et al. Tumor-Infiltrating Macrophages Induce Apoptosis in Activated CD8+ T Cells by a Mechanism Requiring Cell Contact and Mediated by Both the Cell-Associated Form of TNF and Nitric Oxide1 , 2001, The Journal of Immunology.
[59] 鬼塚 正三郎. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody , 1999 .
[60] R. Schreiber,et al. Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.
[61] H. Shinohara,et al. Prognostic value of tumor‐infiltrating dendritic cells expressing CD83 in human breast carcinomas , 2003, International journal of cancer.
[62] Ethan M. Shevach,et al. CD4+CD25+ suppressor T cells: more questions than answers , 2002, Nature Reviews Immunology.
[63] P. Cresswell,et al. Mechanisms of MHC class I--restricted antigen processing. , 1998, Annual review of immunology.
[64] J. Ochoa,et al. l-Arginine Consumption by Macrophages Modulates the Expression of CD3ζ Chain in T Lymphocytes1 , 2003, The Journal of Immunology.
[65] T. Schumacher,et al. Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.
[66] V. Cerundolo,et al. Plasmacytoid dendritic cells prime IFN‐γ‐secreting melanoma‐specific CD8 lymphocytes and are found in primary melanoma lesions , 2003, European journal of immunology.
[67] J. Trapani,et al. A fresh look at tumor immunosurveillance and immunotherapy , 2001, Nature Immunology.
[68] T. Curiel,et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells , 2001, Nature Medicine.
[69] T. Giese,et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. , 2003, Cancer research.
[70] Nina Bhardwaj,et al. Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells , 2001, The Journal of experimental medicine.
[71] K. Black,et al. Induction of a CD4+ T Regulatory Type 1 Response by Cyclooxygenase-2-Overexpressing Glioma1 , 2004, The Journal of Immunology.
[72] Youjin Lee,et al. Priming of naive T cells inside tumors leads to eradication of established tumors , 2004, Nature Immunology.
[73] Rolf M. Zinkernagel,et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction , 2001, Nature.
[74] T. Shono,et al. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. , 2001, Cancer research.
[75] A. Castonguay,et al. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. , 1997, Carcinogenesis.
[76] Angela Panoskaltsis-Mortari,et al. Human Plasmacytoid Dendritic Cells Activated by CpG Oligodeoxynucleotides Induce the Generation of CD4+CD25+ Regulatory T Cells1 , 2004, The Journal of Immunology.
[77] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[78] S. Adams,et al. Manipulating dendritic cell biology for the active immunotherapy of cancer. , 2004, Blood.
[79] Y. Belkaid,et al. Role for CD4+ CD25+ Regulatory T Cells in Reactivation of Persistent Leishmaniasis and Control of Concomitant Immunity , 2004, The Journal of experimental medicine.
[80] J. Banchereau,et al. In Breast Carcinoma Tissue, Immature Dendritic Cells Reside within the Tumor, Whereas Mature Dendritic Cells Are Located in Peritumoral Areas , 1999, The Journal of experimental medicine.
[81] Jeffrey A. Bluestone,et al. Opinion-regulatory lymphocytes: Natural versus adaptive regulatory T cells , 2003, Nature Reviews Immunology.
[82] C. Figdor,et al. Dendritic cell immunotherapy: mapping the way , 2004, Nature Medicine.
[83] R. Steinman,et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. , 1999, The Journal of clinical investigation.
[84] Y. Kawahito,et al. Meloxicam inhibits the growth of non-small cell lung cancer. , 2000, Anticancer research.
[85] Alberto Mantovani,et al. Inflammation and cancer: back to Virchow? , 2001, The Lancet.
[86] K. Seibert,et al. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. , 2000, Cancer research.
[87] R. Steinman,et al. Dendritic cells and the control of immunity , 1998, Nature.
[88] B. Foster,et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[89] S. Mehrotra,et al. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. , 2004, Human immunology.
[90] Lieping Chen,et al. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. , 2004, The Journal of clinical investigation.
[91] A. Raz,et al. Indomethacin Inhibits the Accumulation of Tumor Cells in Mouse Lungs and Subsequent Growth of Lung Metastases , 2000, Chemotherapy.
[92] P. Klenerman,et al. Immune surveillance against a solid tumor fails because of immunological ignorance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[93] H. Adami,et al. Infections as a major preventable cause of human cancer , 2000, Journal of internal medicine.
[94] Christopher Anderson,et al. More questions than answers , 1991, Nature.
[95] M. Gilliet,et al. Generation of Human CD8 T Regulatory Cells by CD40 Ligand–activated Plasmacytoid Dendritic Cells , 2002, The Journal of experimental medicine.
[96] A. Krieg. CpG motifs: the active ingredient in bacterial extracts? , 2003, Nature Medicine.
[97] A. Enk,et al. Induction of Interleukin 10–Producing, Nonproliferating Cd4+ T Cells with Regulatory Properties by Repetitive Stimulation with Allogeneic Immature Human Dendritic Cells , 2000, The Journal of experimental medicine.
[98] Susan M. Kaech,et al. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells , 2001, Nature Immunology.
[99] P. Matzinger,et al. Is cancer dangerous to the immune system? , 1996, Seminars in immunology.
[100] G. Trinchieri,et al. Plasmacytoid dendritic cells in immunity , 2004, Nature Immunology.
[101] Shu-Hsia Chen,et al. Gr-1+ Myeloid Cells Derived from Tumor-Bearing Mice Inhibit Primary T Cell Activation Induced Through CD3/CD28 Costimulation1 , 2000, The Journal of Immunology.
[102] A. Ristimäki,et al. Expression of cyclooxygenase-2 in human lung carcinoma. , 1998, Cancer research.
[103] P. Hwu,et al. The immunotherapy of patients with ovarian cancer. , 2002, Journal of immunotherapy.
[104] Mapping the way , 2002, Trends in Cognitive Sciences.
[105] J. Cheville,et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. , 2003, Cancer research.
[106] D. Carbone,et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.
[107] C. Meijer,et al. Prostanoids Play a Major Role in the Primary Tumor-Induced Inhibition of Dendritic Cell Differentiation , 2002, The Journal of Immunology.
[108] J. Allison,et al. Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.
[109] Haidong Dong,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[110] E. Pamer,et al. CD8 T cell responses to infectious pathogens. , 2003, Annual review of immunology.
[111] M. Feuerer,et al. Bone marrow as a priming site for T-cell responses to blood-borne antigen , 2003, Nature Medicine.
[112] V. Cerundolo,et al. The use of HLA class I tetramers to design a vaccination strategy for melanoma patients , 2002, Immunological reviews.
[113] M. Jenkins,et al. Antigen presentation to naive CD4 T cells in the lymph node , 2003, Nature Immunology.
[114] V. Cerundolo,et al. Dendritic cells: a journey from laboratory to clinic , 2004, Nature Immunology.
[115] L. Karabon,et al. IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity , 2000, British Journal of Cancer.
[116] Yoshimasa Tanaka,et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[117] Ralph S Freedman,et al. Peritoneal inflammation – A microenvironment for Epithelial Ovarian Cancer (EOC) , 2004, Journal of Translational Medicine.
[118] Leonard C. Harrison,et al. Regulatory lymphocytes: Antigen-induced regulatory T cells in autoimmunity , 2003, Nature Reviews Immunology.
[119] H. Choy,et al. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? , 2003, Journal of the National Cancer Institute.
[120] Lieping Chen. Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity , 2004, Nature Reviews Immunology.
[121] O. Finn,et al. Cancer vaccines: between the idea and the reality , 2003, Nature Reviews Immunology.
[122] T. Curiel,et al. Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.
[123] P. Borrow,et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon , 2003, Nature Immunology.
[124] P. Carmeliet,et al. Dendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer , 2004, Cancer Research.
[125] F. Sallusto,et al. The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. , 2001, Current opinion in immunology.
[126] Stephen P. Schoenberger,et al. Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation , 2001, Nature Immunology.
[127] G. Coukos,et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. , 2001, Cancer research.
[128] G. Ogg,et al. Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes , 1998, The Journal of experimental medicine.
[129] T. Tüting,et al. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. , 2001, Cancer research.
[130] J. Shimizu,et al. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.
[131] M. Lotze,et al. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. , 2001, Cancer research.
[132] S. H. van der Burg,et al. Strategies for immunotherapy of cancer. , 2000, Advances in immunology.
[133] Michael T. Lotze,et al. Inflammation and necrosis promote tumour growth , 2004, Nature Reviews Immunology.
[134] D. Keskin,et al. Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase , 2002, Science.
[135] Michel C. Nussenzweig,et al. Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo , 2001, The Journal of experimental medicine.
[136] David F. Richards,et al. In Vitro Generation of Interleukin 10–producing Regulatory CD4+ T Cells Is Induced by Immunosuppressive Drugs and Inhibited by T Helper Type 1 (Th1)– and Th2-inducing Cytokines , 2002, The Journal of experimental medicine.
[137] Hua Yu,et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.
[138] T. Luger,et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. , 1999, Journal of immunology.
[139] F. Foss. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. , 2000, Clinical lymphoma.
[140] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[141] P. Loke,et al. B7x: A widely expressed B7 family member that inhibits T cell activation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[142] D. Schmitt,et al. Gangliosides from Human Melanoma Tumors Impair Dendritic Cell Differentiation from Monocytes and Induce Their Apoptosis , 2003, The Journal of Immunology.
[143] J J Padgett,et al. A renewed sense of self. , 1994, Journal of psychosocial nursing and mental health services.
[144] V. Bronte,et al. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. , 2001, Journal of immunotherapy.
[145] Hervé Groux,et al. A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis , 1997, Nature.
[146] G. Zhu,et al. B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. , 2001, Blood.
[147] U. Grohmann,et al. CTLA-4–Ig regulates tryptophan catabolism in vivo , 2002, Nature Immunology.
[148] J. Brayer,et al. Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses , 2004, Cancer Research.